Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novartis AG Signs Deal To Boost Cell Therapy Portfolio-Reuters


Friday, 6 Sep 2013 01:48am EDT 

Reuters reported that Novartis AG said it has signed a licensing and research deal that could boost its ability to develop new cell-based therapies for conditions where little treatment is currently available. The Company said it would use a stem-cell based platform developed by U.S.-based biopharmaceutical company Regenerex to help broaden its cell therapy portfolio.